LOGIN  |  REGISTER
Terns Pharmaceuticals
Chimerix

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

June 06, 2024 | Last Trade: C$0.57 0.00 0.00

LAVAL, Quebec / Jun 06, 2024 / Business Wire / Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 5, 2024. The detailed results of the votes received by proxy are as follows:

Election of Directors

 

Director Nominees


NUMBER OF SHARES


PERCENTAGE OF VOTES CAST


FOR


WITHHELD


FOR


WITHHELD

Daniel N. Chicoine

6,490,732

109,026

98.3%

1.7%

Anthony E. Dobranowski

6,508,888

90,870

98.6%

1.4%

John C. London

6,533,190

66,568

99.0%

1.0%

Deborah Shannon-Trudeau

6,541,297

58,461

99.1%

0.9%

Serge Verreault

6,590,211

9,547

99.9%

0.1%

Reappointment of External Auditors

 

Outcome


NUMBER OF SHARES


PERCENTAGE OF VOTES CAST


FOR


WITHHELD


FOR


WITHHELD

Ernst & Young LLP reappointed

7,212,551

148,556

98.0%

2.0%

Approval of the Continuation of Crescita’s Share Incentive Plan

 

Outcome


NUMBER OF SHARES


PERCENTAGE OF VOTES CAST


FOR


AGAINST


FOR


AGAINST

Share Incentive Plan approved

6,526,477

73,281

98.9%

1.1%

About Crescita Therapeutics Inc.

Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.

Chimerix

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB